Ivan Fomin

Ivan Fomin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Plants
Verified
Journal Article
Open access
PDF file
Ulyana S. ZubairovaUlyana S. Zubairova
Ulyana S. Zubairova
IFIvan Fomin
Ivan Fomin
KKKristina A. Koloshina
Kristina A. Koloshina
ABAlisa I. Barchuk
Alisa I. Barchuk
TETatyana V. Erst
Tatyana V. Erst
Alexey DoroshkovAlexey Doroshkov
Alexey Doroshkov
The epidermal leaf patterns of plants exhibit remarkable diversity in cell shapes, sizes, and arrangements, driven by environmental interactions that lead to significant adaptive changes even among closely related species. The Solanaceae family, known for its high diversity of adaptive epidermal structures, has traditionally been studied using qualitative phenotypic descriptions. To advance this, we developed a workflow combining multi-scale computer vision, image processing, and data analysis to extract digital descriptors for leaf epidermal cell morphology. Applied to nine wild potato species, this workflow quantified key morphological parameters, identifying descriptors for trichomes, stomata, and pavement cells, and revealing interdependencies among these traits. Principal component analysis (PCA) highlighted two main axes, accounting for 45% and 21% of variance, corresponding to features such as guard cell shape, trichome length, stomatal density, and trichome density. These axes aligned well with the historical and geographical origins of the species, separating southern from Central American species, and forming distinct clusters for monophyletic groups. This workflow thus establishes a quantitative foundation for investigating leaf epidermal cell morphology within phylogenetic and geographic contexts.

1 September 2025 in AoB Plants
Verified
Journal Article
Open access
AEAnastasiya Egorova
Anastasiya Egorova
IFIvan Fomin
Ivan Fomin
AFAnastasia Fizikova
Anastasia Fizikova
NKNina Kostina
Nina Kostina
LMLyudmila Malyukova
Lyudmila Malyukova
SGSophia V. Gerasimova
Sophia V. Gerasimova
Gene-editing tools enable precise, targeted genome modifications, providing new approach for the rapid and sustainable improvement of tea plant (Camellia sinensis (L.) Kuntze). Developing such an approach is especially important due to the perennial nature and complex genetics of the tea plant, which make traditional breeding slow and inefficient. To validate a gene editing protocol in the elite local tea cultivar Kolkhida three candidate genes were selected. Two guide RNAs (gRNAs) were designed for each gene, and corresponding constructs for targeted genome modification in tea were generated. Successful modifications of the target sequences in cv. Kolkhida tea protoplasts were achieved for all three target genes. The high mutagenic efficiency of the selected gRNAs was observed for two out of three genes, including induction of precise deletions between target motifs. gRNAs were delivered in protoplasts via co-transfection technique, and combined gRNA activity was observed when transfection efficiency exceeded 28%. The genome modification method for tea protoplasts established in this study can serve as a screening protocol to evaluate the in vivo efficiency of different genome editing approaches in the tea plant.

28 February 2025 in Voprosy onkologii
Verified
Journal Article
Open access
IFIvan Fomin
Ivan Fomin
СКСергей Петрович Коваленко
Сергей Петрович Коваленко
В данной статье на основе анализа литературных данных рассмотрена клиническая обоснованность выбора минорных мутаций в гене KRAS при колоректальном раке перед анти-EGFR терапией. Показано, что на сегодняшний день нет однозначных результатов клинических исследований, которые бы демонстрировали клиническую значимость всех известных мутаций в кодонах 59, 61, 117, 146 гена KRAS при колоректальном раке. Приводятся данные, которые обосновывают минимизацию необходимого и достаточного списка минорных мутаций в гене KRAS, анализ которых полностью обоснован на основании клинических данных. В заключении отмечается, что анализ мутаций перед использованием анти-EGFR терапии не имеет статистически значимых клинических обоснований для мутаций A146V, A146P и не обоснован для всех мутаций в кодоне 59 гена KRAS.